The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
REGULATORY
Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
The Japanese government should quickly reinstate what it calls an “active recommendation” for HPV vaccines, which has been withheld for as long as seven years now, a league of ruling Liberal Democratic Party (LDP) lawmakers campaigning for just that said…
To read the full story
Related Article
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- MSD Japan Hails Resumption of HPV Vaccine Recommendation
November 29, 2021
- Japan to Reinstate Recommendation for HPV Vaccination in April
November 29, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- Japan to Reinstate HPV Vaccine Recommendation after 8 Years in Limbo
November 15, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
- MHLW Panel to Discuss HPV Vaccine Recommendation on Oct. 1
September 29, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
- MSD Urges Govt to Start HPV Vaccine Discussions as Soon as Possible
September 2, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
- Govt Recognizes Need to Resume HPV Vaccine Discussion: Health Minister
August 31, 2021
- Reinstate Active HPV Vaccine Promotion before October: LDP League
August 27, 2021
- LDP League Submits Request to Reinstate HPV Vaccine Promotion
March 30, 2021
- LDP Group to Submit Request for HPV Vaccine Promotion Resumption
March 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
- HPV Vaccines Clinically Significant in Japan, PMDA Says in Silgard 9 Review Report
July 28, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
- Japan Approval for MSD’s 9-Valent HPV Vaccine Delayed into July
June 30, 2020
- Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
June 26, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- MSD’s 9-Valent HPV Vaccine Up for Review in 1st Online PAFSC Meeting
April 16, 2020
- MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
REGULATORY
- Japan Begins Second COVID Booster for Age 60-Plus, High-Risk Adults
May 26, 2022
- MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
- Japan Panel OKs Risk Management Measures for Potential Revlimid Generics
May 25, 2022
- MHLW to Issue Guidances on eConsent, Drug Delivery for Virtual Clinical Trials: Official
May 25, 2022
- Japan Regulators Warn of Monkeypox Cases
May 25, 2022
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…